Carboxypeptidase A-4 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human Carboxypeptidase A4 (CPA4, UniProt Q9UI42), expressed in HEK293 cells. Full-length 421-aa secreted metalloexopeptidase; suited for substrate cleavage assays, inhibitor profiling, and antibody validation.
Expression system
HEK293
Cat. #
REC-CarboxypeptidaseA4

In stock

SKU
REC-CarboxypeptidaseA4
$498.00

Target Overview

Carboxypeptidase A4 (CPA4; UniProt Q9UI42) is a secreted zinc-dependent metalloexopeptidase encoded by the CPA4 gene and belonging to the M14 carboxypeptidase family. The full-length human protein spans 421 amino acids and, like other A-type carboxypeptidases, requires a zinc ion at its active site for catalytic activity. This recombinant form is produced in HEK293 mammalian cells, which support the glycosylation and disulfide-bond formation expected of a secreted protease, yielding a product with native-like folding relevant to enzymatic activity studies. CPA4 preferentially cleaves hydrophobic C-terminal residues, with documented selectivity for -Phe, -Leu, -Ile, -Met, -Tyr, and -Val. This substrate preference positions it functionally alongside other extracellular carboxypeptidases implicated in peptide hormone and neuropeptide catabolism. In the laboratory, this recombinant protein is used primarily in three contexts. First, researchers run fluorometric or colorimetric exopeptidase activity assays using synthetic chromogenic substrates (e.g., hippuryl-Phe or hippuryl-Leu derivatives) to characterise kinetic parameters (Km, kcat, Vmax) and benchmark inhibitor potency. Second, the protein serves as a defined enzyme source in small-molecule inhibitor IC50 determinations and structure–activity relationship (SAR) studies. Third, it functions as a validated positive-control antigen for antibody characterisation; researchers using the matched Triple Point Biologics antibody (SKU: RP-CarboxypeptidaseA4) — validated for Western blot against human CPA4 — can use this recombinant to confirm antibody specificity, titrate signal, and establish band-size expectations on immunoblots. The HEK293 expression system is particularly appropriate here because glycoforms are closer to endogenous human CPA4 than E. coli or insect-cell-derived preparations, reducing ambiguity in apparent molecular weight comparisons.

Background

CPA4 is a secreted metalloexopeptidase that removes hydrophobic C-terminal residues from peptide substrates, implicating it in the post-translational processing of peptide hormones and neuropeptides. Although its full physiological substrate repertoire remains under active investigation, its secreted localisation and broad specificity for bulky hydrophobic residues make it a candidate regulator of extracellular peptide signalling. CPA4 has attracted growing attention as a research target in oncology. The gene maps to chromosome 7q32, a region subject to genomic imprinting and epigenetic regulation. Differential methylation and allele-specific expression of CPA4 have been documented across multiple tissue contexts, and aberrant imprinting at this locus has been examined in reproductive biology — including studies of DNA methylation patterns in recurrent miscarriage across sperm and fetal-maternal tissues (Niu et al., 2025, PeerJ). Allelic expression analyses in cancer cell lines spanning multiple histologies have similarly identified CPA4 among genes exhibiting altered expression patterns, suggesting that epigenetic dysregulation of this locus is a broader phenomenon across tumour types (Krushkal et al., 2025, Clin Epigenetics). At the protein level, Adeluola et al. (2025, Cancers) have characterised CPA4 as a biomarker associated with cancer aggressiveness and drug resistance, providing a detailed account of its expression across tumour types and its potential utility as a stratification marker in translational research settings. Separately, genome-wide Mendelian randomisation studies integrating plasma proteomics with GWAS data have nominated CPA4 as a candidate causal protein in hepatocellular carcinoma (Chen et al., 2026, Medicine) and identified it among druggable targets in lung squamous cell carcinoma through eQTL/pQTL integration (Cheng et al., 2025, Sci Rep). These findings position CPA4 as a protein of interest for researchers investigating proteomic drivers of tumour progression, though the mechanistic basis of these associations remains an area of ongoing basic research. For in-vitro studies, the availability of a well-characterised recombinant CPA4 protein expressed in a mammalian system enables direct enzymatic interrogation — substrate specificity mapping, inhibitor profiling, and comparative kinetics with related M14-family members such as CPA1, CPA2, and CPB. Researchers requiring an antibody reagent complementary to this recombinant can cross-reference the matched Triple Point Biologics CPA4 antibody (SKU: RP-CarboxypeptidaseA4), which has been validated for Western blot against human CPA4, with predicted reactivity informed by sequence conservation analysis.

Applications

  • Exopeptidase activity assay using hippuryl-Phe or hippuryl-Leu chromogenic substrates to determine Km and kcat
  • Small-molecule inhibitor IC50 determination and SAR profiling against the CPA4 active site
  • Substrate specificity mapping via synthetic peptide panels with hydrophobic C-terminal residues (-Phe, -Leu, -Ile, -Met, -Tyr, -Val)
  • Positive-control antigen for Western blot validation of anti-CPA4 antibodies, including the matched Triple Point Biologics antibody (RP-CarboxypeptidaseA4)
  • IHC antibody titration and signal calibration using recombinant CPA4 as a defined antigen standard
  • Comparative kinetics with M14-family carboxypeptidases (CPA1, CPA2, CPB) to assess family-member selectivity of inhibitors
  • Biophysical characterisation (SPR, ITC, or thermal shift) of small-molecule or peptide inhibitor binding to CPA4

References

  1. Adeluola AA et al. Carboxypeptidase A4: A Biomarker for Cancer Aggressiveness and Drug Resistance. Cancers (Basel). 2025. doi:10.3390/cancers17152566 PMID: 40805261
  2. Chen X et al. Integrating plasma proteomes with genome-wide association data for causal protein identification in hepatocellular carcinoma: A bidirectional Mendelian randomization study. Medicine (Baltimore). 2026. doi:10.1097/MD.0000000000047315 PMID: 41578465
  3. Cheng S et al. Druggable genome-wide Mendelian randomization integrating GWAS and eQTL/pQTL data identifies targets for lung squamous cell carcinoma. Sci Rep. 2025. doi:10.1038/s41598-025-15977-8 PMID: 40820226
  4. Krushkal J et al. Allelic expression patterns of imprinted and non-imprinted genes in cancer cell lines from multiple histologies. Clin Epigenetics. 2025. doi:10.1186/s13148-025-01883-3 PMID: 40414875
  5. Niu Y et al. Comprehensive analysis of DNA methylation patterns in recurrent miscarriage: imprinted/non-imprinted genes and their regulation across sperm and fetal-maternal tissues. PeerJ. 2025. doi:10.7717/peerj.20125 PMID: 41081108

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Secreted (most); lysosome (some)

Frequently Asked Questions

What is the expected molecular weight of recombinant Carboxypeptidase A-4 on SDS-PAGE?

The full-length human CPA4 protein (UniProt Q9UI42) encodes 421 amino acids, giving a calculated molecular weight of approximately 47 kDa. Because this recombinant is produced in HEK293 mammalian cells, N-linked glycosylation is expected, and the apparent band on reducing SDS-PAGE typically migrates at 50–55 kDa. If you are running a Western blot positive control alongside our matched antibody (RP-CarboxypeptidaseA4), expect the dominant band in that 50–55 kDa window. A faint pro-form band may appear slightly higher depending on processing efficiency in the HEK293 expression system.

Is recombinant CPA4 expressed as a zymogen or an active mature form?

CPA4, like other secreted A-type carboxypeptidases, is synthesized as an inactive proenzyme carrying an N-terminal propeptide that occludes the active site. This recombinant is produced in HEK293 cells under conditions that promote secretion and propeptide processing, yielding predominantly the mature, active form. The mature chain runs slightly smaller than the full-length 421-aa sequence on SDS-PAGE (~47 kDa calculated, ~50–55 kDa apparent with glycosylation). If your experimental model requires the zymogen form specifically, contact us — but for standard activity assays, this product is supplied ready to use as an active enzyme.

What substrates does recombinant Carboxypeptidase A-4 cleave in a fluorometric activity assay?

CPA4 preferentially cleaves hydrophobic C-terminal residues, with documented selectivity for -Phe, -Leu, -Ile, -Met, -Tyr, and -Val. For fluorometric assays, the synthetic substrate N-(4-methoxyphenylazoformyl)-Phe-OH (MAPF) is widely used and compatible with CPA4's substrate preference. Abz-Gly-Phe(NO2) peptide substrates are also reported. Run initial Km determinations at substrate concentrations ranging from 10 µM to 1 mM in assay buffer. Fluorescence should be monitored at excitation ~320 nm / emission ~420 nm depending on your fluorophore pair. Include 1 mM EDTA as a no-zinc negative control to confirm zinc-dependent activity.

What activity assay buffer should I use for recombinant CPA4 and does the storage buffer interfere?

A standard assay buffer for CPA4 activity is 50 mM Tris-HCl pH 7.5, 100–150 mM NaCl, 0.5–1 mM ZnCl2. The product storage buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol, 5 mM CaCl2) is generally compatible at dilutions ≥1:10 into assay buffer; glycerol carry-over below 1% (v/v) does not meaningfully inhibit activity. Avoid EDTA or EGTA in assay buffers, as chelation of the catalytic zinc ion abolishes activity. If you need to switch buffers, dialysis or a desalting spin column equilibrated in assay buffer is appropriate prior to Km/kcat determination.

What starting enzyme concentration should I use for a CPA4 inhibitor IC50 assay?

For IC50 determinations, we recommend titrating the enzyme to identify the concentration that produces a linear signal increase over 30–60 minutes under your substrate conditions. A practical starting point is 0.5–5 nM recombinant CPA4 with substrate at or below the Km (typically 50–200 µM for MAPF-type substrates). Using enzyme well below substrate concentration avoids substrate depletion artifacts and keeps you in the linear regime required for accurate Ki extrapolation. Pre-incubate inhibitor with enzyme for 15–30 minutes at 37°C before substrate addition to capture slow-binding inhibitors. Run at minimum in triplicate with a DMSO vehicle control ≤0.5% (v/v).

Can I use recombinant Carboxypeptidase A-4 as a Western blot positive control for the RP-CarboxypeptidaseA4 antibody?

Yes — this is one of the primary intended uses of REC-CarboxypeptidaseA4 alongside RP-CarboxypeptidaseA4 (/anti-carboxypeptidase-a4-rabbit-polyclonal-antibody). The matched rabbit polyclonal antibody was raised and validated in the same lab, and the two products are guaranteed compatible for Western blot positive control experiments. Load 10–50 ng of recombinant CPA4 per lane on a standard 10–12% SDS-PAGE gel. Under reducing conditions, expect a band at 50–55 kDa. This provides a clean, reproducible positive control lane that confirms antibody performance and helps calibrate signal intensity against your cell lysate or tissue samples.

How much recombinant CPA4 should I load per lane for Western blot, and at what antibody dilution?

Start with 20–50 ng of REC-CarboxypeptidaseA4 per lane. Because HEK293-expressed recombinant is a defined, purified protein (>90% by SDS-PAGE), it produces a strong, clean band compared to endogenous CPA4 in tissue lysates, so titrate down if signal is saturating. Pair with RP-CarboxypeptidaseA4 at the dilution specified on that product's datasheet (typically 1:500–1:2000 in 5% non-fat milk or BSA/TBST). Run the recombinant control in an adjacent lane to your experimental samples. Use HRP-conjugated anti-rabbit secondary at 1:5,000–1:10,000. Confirm that the band co-migrates with your endogenous CPA4 signal.

How should I store and handle recombinant CPA4 to preserve enzymatic activity long-term?

REC-CarboxypeptidaseA4 is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol, 5 mM CaCl2, and shipped on dry ice. Upon receipt, store at -20°C in the single-use aliquots provided. Avoid repeated freeze-thaw cycles, as they progressively reduce metalloexopeptidase activity — each cycle can cause measurable losses. For experiments requiring multiple uses from the same preparation, prepare working dilutions in assay buffer, keep on ice, and discard unused diluted material at end of session. Do not add carrier BSA unless specifically needed, as it can interfere with downstream activity or binding assays. Shelf life is 12 months from receipt when stored correctly.

Validation imagery coming soon

Western blot validation figures for REC-CarboxypeptidaseA4 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →